The Day Ahead newsletter:
The Morning News Call newsletter:
At 8:00 ET, Dow e-minis were up 0.70 percent at 26,315. S&P 500 e-minis were up 0.50 percent at 2,906.25, while Nasdaq 100 e-minis were up 0.41 percent at 7,648.5.
The top three NYSE percentage gainers premarket :
** Anadarko Petroleum Corp , up 31.2 pct
** Qudian Inc , up 9.5 pct
** Laredo Petroleum Inc , up 8.4 pct
The top two NYSE percentage losers premarket :
** Four Seasons Education (Cayman) Inc , down 7.3 pct
** Resideo Technologies Inc , down 7.3 pct
The top three Nasdaq percentage gainers premarket :
** Vantage Energy Acquisition Corp , up 100.0 pct
** Vital Therapies Inc , up 53.2 pct
** Taronis Technologies Inc , up 41.5 pct
The top three Nasdaq percentage losers premarket :
** Reebonz Holding Limited , down 50.9 pct
** Tracon Pharmaceuticals Inc , down 49.1 pct
** X4 Pharmaceuticals Inc , down 27.8 pct
** Anadarko Petroleum Corp : up 31.2 pct premarket
Anadarko Petroleum: Jumps as Chevron swoops in with $33 bln deal
** JPMorgan & Chase Co : up 2.6 pct premarket
JPMorgan shares add to gain after better-than-expected Q1 results
** Walt Disney Co : up 5.4 pct premarket
Disney: Shares advance after aggressive streaming push
** Nike Inc : up 0.6 pct premarket
Nike: Olympics 2020 sales to be a positive catalyst - JP Morgan
** X4 Pharmaceuticals Inc : down 27.8 pct premarket
X4 Pharmaceuticals: Slides on stock-and-warrants offering plan
** Alaska Air Group Inc : up 1.1 pct premarket
Alaska Air Group: Up after raising Q1 unit revenue outlook
** Allegheny Technologies Inc : down 3.8 pct premarket
Allegheny Technologies: Down after flagging Q1 profit below estimates
** Mosaic Co : down 1.9 pct premarket
Mosaic: Dips on halting Brazil production following new rules around dams
** X4 Pharmaceuticals Inc : down 27.8 pct premarket
X4 Pharma: Drops on planned deep-discounted equity raise
** Amyris Inc : down 20.4 pct premarket
Amyris: Slumps after disclosing accounting errors
** TRACON Pharmaceuticals Inc : down 49.1 pct premarket
Tracon Pharma tumbles after terminating late-stage cancer study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
